Gene · 8405
Papers2,215
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 2,215
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| ZOMES: expanding roles of the PCI complexes from protein metabolism to drug discovery. | NPJ Metab Health Dis | 2026 | 41760881 | PubTator, text mining | PubMed |
| Prediction Analysis of Microarray of 50 genes (PAM50) classifier validated for predicting prostate cancer progression in active surveillance: Miami Active Surveillance Trial (MAST). | BJU Int | 2026 | 41757539 | PubTator, text mining | PubMed |
| Functional roles and mechanisms of circRNA-protein interactions in cancer progression and tumor immune regulation. | Front Immunol | 2026 | 41756268 | PubTator, text mining | PubMed |
| Clinicogenomic Insights for Progression-Free Survival in Prostate Cancer. | Int J Environ Res Public Health | 2026 | 41752338 | PubTator, text mining | PubMed |
| PD-L1 Expression in Prostate Cancer: Anatomopathological Features, Methodological Pitfalls, and Therapeutic Potential. | Int J Mol Sci | 2026 | 41751934 | PubTator, text mining | PubMed |
| Molecular mechanisms and classification of castration-resistant prostate cancer: Insights into androgen receptor, cancer stem cells, and neuroendocrine features. | Curr Urol | 2026 | 41743916 | PubTator, text mining | PubMed |
| Intratumoral Androgens and Genetic Variants Driving Therapy Resistance in Prostate Cancer. | Research (Wash D C) | 2026 | 41743623 | PubTator, text mining | PubMed |
| Emerging therapies to overcome antiandrogen resistance and beyond in lethal prostate cancer. | J Natl Cancer Cent | 2026 | 41738039 | PubTator, text mining | PubMed |
| Alterations in AR-FOXA1 signaling in prostate cancer progression and therapeutic resistance. | J Natl Cancer Cent | 2026 | 41738032 | PubTator, text mining | PubMed |
| Transcriptional and epigenetic reprogramming, lineage plasticity and therapy resistance in prostate cancer. | J Natl Cancer Cent | 2026 | 41738031 | PubTator, text mining | PubMed |
| Genetic loss of CHD1 regulates distinct histone post-translational modifications in the development of castration-resistant prostate cancer. | Neoplasia | 2026 | 41720070 | PubTator, text mining | PubMed |
| Harnessing Ribonucleoprotein Granule Biology for Cancer Therapy: The Central Role of Protein Modifications. | Research (Wash D C) | 2026 | 41716844 | PubTator, text mining | PubMed |
Re: Rui M. Bernardino, Leyi B. Yin, Katherine Lajkosz, et al. Intraductal Carcinoma Predicts Poor Response to Neoadjuvant Therapy in High-risk Prostate Cancer: A Retrospective Analysis of a Prospective Trial. Eur Urol Open Sci 2025;82:52-8. | Eur Urol Open Sci | 2026 | 41716568 | PubTator, text mining | PubMed |
| Molecular insights for the tumor suppressor role of SPOP in prostate cancer. | Biochim Biophys Acta Rev Cancer | 2026 | 41707797 | PubTator, text mining | PubMed |
| Outcomes for Patients With SPOP Mutated Castration-Resistant Prostate Cancer (CRPC) Treated With an Androgen Receptor Pathway Inhibitor (ARPI). | Clin Genitourin Cancer | 2026 | 41667321 | PubTator, text mining | PubMed |
| Ubiquitin control of cytosolic DNA sets immune responses to DNA damage. | Cancer Cell | 2026 | 41666875 | PubTator, text mining | PubMed |
| Emerging biologic modalities for targeted protein degradation. | J Biol Chem | 2026 | 41651431 | PubTator, text mining | PubMed |
| Tiny tools closing the gap: nanobodies in research and therapy. | Function (Oxf) | 2026 | 41627946 | PubTator, text mining | PubMed |
| Exploring the biology of metastatic hormone-sensitive prostate cancer: on the road to precision medicine. | J Clin Invest | 2026 | 41623173 | PubTator, text mining | PubMed |
| Proanthocyanidins enhance antitumor immunity by promoting ubiquitin-proteasomal PD-L1 degradation via stabilization of LKB1 and SYVN1. | J Clin Invest | 2026 | 41623165 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8405/papers?page=3